Costa Rita (Orcid ID: 0000-0003-0710-3611)

Doryab Ali (Orcid ID: 0000-0002-5976-5361)

De Santis Martina (Orcid ID: 0000-0002-0733-2599)

Königshoff Melanie (Orcid ID: 0000-0001-9414-5128)

Title: A drug screen with approved compounds identifies amlexanox as a novel Wnt/β-catenin activator inducing lung epithelial organoid formation

Running title: Amlexanox activates Wnt/β-catenin signaling and initiates lung repair

Authors: Rita Costa[1,7], Darcy E. Wagner[1,8], Ali Doryab[1,2], Martina M. De Santis[1,8], Kenji Schorpp[3], Ina Rothenaigner[3], Mareike Lehmann[1], Hoeke A. Baarsma[1,9], Xueping Liu[4], Otmar Schmid[2], Monica Campillos[4], Ali Önder Yildirim[5], Kamyar Hadian[3] and Melanie Königshoff[1,6]

Author affiliations:

1. Research Unit Lung Repair and Regeneration, Helmholtz Zentrum München, German Research Center for Environmental Health, Ludwig-Maximilians-University, University Hospital Grosshadern, Member of the German Center of Lung Research (DZL), Munich, Germany.

2. Pulmonary Aerosol Delivery, Institute of Lung Biology and Disease, Comprehensive Pneumology Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Member of the German Center for Lung Research (DZL), Munich, Germany.

3. Assay Development and Screening Platform, Institute for Molecular Toxicology and Pharmacology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.

4. Institute of Structural Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.

5. Immunopathology of COPD, Institute of Lung Biology and Disease, Comprehensive Pneumology Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Member of the German Center for Lung Research (DZL), Munich, Germany.

6. University of Pittsburgh, Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Pittsburgh, PA, USA.

7. Current address: Institute of Virology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.

8. Current address: Department of Experimental Medical Sciences, Wallenberg Centre for Molecular Medicine, Faculty of Medicine, Stem Cell Centre, Lund University, Lund, Sweden.

9. Current address: Department of Molecular Pharmacology, Groningen Research Institute for Asthma and COPD, University Medical Center Groningen, University of Groningen, Groningen, Netherlands

Word count: 3253 (introduction 513, results 1165, discussion and conclusion 1575).

Abstract

Background and Purpose: Emphysema is an incurable disease characterized by loss of lung tissue leading to impaired gas exchange. Wnt/β-catenin signaling is reduced in emphysema and exogenous activation of the pathway in experimental models *in vivo* and in human *ex vivo* lung tissue improves lung function and structure. We sought to identify a pharmaceutical able to activate Wnt/β-catenin signaling and asses its potential to activate lung epithelial cells and repair.

Experimental Approach: We screened 1216 human-approved compounds for Wnt/β-catenin signaling activation using luciferase reporter cells, and selected candidates based on their computational predicted protein targets. We further performed confirmatory luciferase reporter and metabolic activity assays. Finally, we studied the regenerative potential in murine adult epithelial cell derived lung organoids and *in vivo* using a murine elastase-induced emphysema model.

Key Results: The primary screen identified 16 compounds that significantly induced Wnt/β-catenin-dependent luciferase activity. Selected compounds activated Wnt/β-catenin signaling without inducing cell toxicity or proliferation. Two compounds were able to promote organoid formation, which was reversed by pharmacological Wnt/β-catenin inhibition, confirming the Wnt β-catenin-dependent mechanism of action. Amlexanox was used for *in vivo* evaluation and preventive treatment resulted in improved lung function and structure in emphysematous mouse lungs. Moreover, gene expression of *Hgf*, an important alveolar repair marker, was increased, whereas disease marker *Eln* was decreased, indicating that amlexanox induces pro-regenerative signaling in emphysema.

Conclusion and Implications: Using a drug screen based on Wnt/β-catenin activity, organoid assays, and a murine emphysema model, amlexanox was identified as a novel potential therapeutic for emphysema.

Abbreviations: Adamts4, A disintegrin and metalloproteinase with thrombospondin motifs 4; COPD, chronic obstructive pulmonary disease; Eln, elastin; EMA, European Medicine Agency; FDA, Food and Drug Administration; Fgf7, fibroblast growth factor 7; Fzd4, frizzled class receptor 4; GSK-3β, glycogen synthase kinase-3 β; HGF, hepatocyte growth factor; IKK, IkappaB kinase; IRF3, interferon regulatory factor 3; LEF, lymphoid enhancer-binding factors; LiCl, lithium chloride; TBK1, TANK binding kinase 1; TCF, T-cell factor.

Bullet point summary

What is already known:

- Wnt/β-catenin signaling is down-regulated in emphysematous COPD patient's lungs and is a potential therapeutic target to induce tissue repair

What this study adds:

- proof of concept study which identifies a drug activating Wnt/β-catenin signaling and initiating lung repair
- utility of lung organoids for pro-regenerative drug discovery in emphysema and COPD

Clinical significance:

- amlexanox, an approved drug with potential for emphysema treatment, can rapidly translate into the clinics

Introduction

Respiratory diseases are increasing in prevalence and are associated with mortality, representing a medical challenge with unmet needs (Li, Cao, Guo, Xie & Liu, 2020). Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the world (Quaderi & Hurst, 2018) with two main characteristics: small airway disease and emphysema. The main risk factors for COPD include cigarette smoke, advanced age and long-term exposure to air pollutants and chemicals. Defined as a clinical syndrome which manifests as a heterogeneous and slowly progressing lung disease, COPD results in airflow limitation, as well as excessive inflammation and parenchymal tissue destruction. The tissue damage in the alveolar region is called emphysema, which results in a reduction of the gas exchange area of the lung (Agusti & Hogg, 2019; Celli & Wedzicha, 2019). Lung transplantation is the only curative treatment option for COPD. However, organ availability, candidate criteria and eligibility, as well as tissue rejection and other associated complications make lung transplantation an unreliable treatment for most cases (Siddiqui & Diamond, 2018). Other treatment options, such as bronchodilators, are effective in relieving symptoms but are unable to reverse disease progression (Singh et al., 2019).

As with other respiratory diseases, there are great challenges in the development of effective therapies for emphysema/COPD. Over the past 40 years, many of the drugs introduced for the treatment of COPD have been improvements of existing drug classes, like for instance, inhaled corticosteroids and long acting β2-agonists (Barnes, Bonini, Seeger, Belvisi, Ward & Holmes, 2015). Repurposing old drugs is an attractive approach to accelerate drug development (Pushpakom et al., 2019).

Regenerative pharmacology for COPD has been discussed in the lung field (Hind & Maden, 2011; Ng-Blichfeldt, Gosens, Dean, Griffiths & Hind, 2019). Different studies suggest the lung remains largely quiescent after development, but that upon injury, multiple cell types can proliferate and restore the lung structure (Liu et al., 2019; Nabhan, Brownfield, Harbury,

Krasnow & Desai, 2018; Zacharias et al., 2018). The signaling pathways involved in these processes and their alteration in COPD represents an area of active research.

Wnt/β-catenin signaling is an important pathway during lung development, homeostasis and repair (Baarsma & Konigshoff, 2017). We and others have shown it to be decreased in COPD (Baarsma et al., 2017; Jiang et al., 2016; Kneidinger et al., 2011; Skronska-Wasek et al., 2017; Uhl et al., 2015; Wang et al., 2011). We have also previously demonstrated that Wnt/β-catenin signaling is a promising target for lung repair in COPD/emphysema both in *in vivo* and *ex vivo* studies, using precision-cut lung slices derived from COPD patients (Kneidinger et al., 2011; Uhl et al., 2015; Conlon et al., 2020). Although lithium chloride (LiCl) and CHIR99021 are two well-known glycogen synthase kinase-3 β (GSK-3β) inhibitors used to experimentally activate Wnt/β-catenin signaling, there are toxicity concerns regarding their systemic use in humans (De Meyer et al., 2011; Uhl et al., 2015).

Here we applied an FDA, EMA and other agencies-approved drug screen to identify novel Wnt/β-catenin signaling activators with the potential to initiate lung repair and thus could be used for the treatment of COPD.

Methods

Cell culture

Leading Light Wnt Reporter cells (Enzo Life Sciences) and NIH/3T3 (ATCC CRL-1658, ATCC, RRID:CVCL_0594) cells, both fibroblast cell lines, were cultured in high glucose Dulbecco's Modified Eagle Medium, DMEM (Gibco), supplemented with 4 mM L-alanyl-L-glutamine dipeptide (Gibco), 10% (w/v) fetal bovine serum, FBS (PAN-Biotech), 100 U ml[1] penicillin and streptomycin (Gibco). For all experiments using NIH/3T3 and Leading Light Wnt Reporter cells, well plates were coated with poly-L-lysine (Sigma-Aldrich). MLg (ATCC CCL206, ATCC, RRID:CVCL_0437) cells were cultured in DMEM/Ham's F12 media (Gibco) supplemented with 10% (w/v) FBS, 100 U ml[1] penicillin and streptomycin. Cells were grown at 37°C with 5% CO_2 in humidified conditions.

High-throughput small compound screen

For the compound screen, Leading Light Wnt Reporter cells stably expressing firefly luciferase under the control of T-cell factor/lymphoid enhancer-binding factors (TCF/LEF) were used (Figure S1). 1×10^4 cells in 50 µl of 10% (w/v) FBS supplemented media were dispensed in white opaque 384-well plates (PerkinElmer) and allowed to adhere for 24 hours (h) at 37°C in 5% CO_2 in humidified conditions. Cells were serum starved with 0.1% (w/v) FBS media for 24 hours to allow for cell synchronization prior to treatment. Cells were then treated for 24 hours with 10 µM of 1216 compounds belonging to the Prestwick Chemical Library (Prestwick chemical) in 0.1% (w/v) FBS-supplemented medium. 1% (w/v) dimethyl sulfoxide, DMSO (Carl Roth), and 10 µM CHIR99021 (Tocris), a GSK-3β inhibitor, were used as negative and positive controls respectively. Media was removed and 25 µl of Bright-Glo Luciferase Assay System (Promega) was added to each well. Luminescence was measured using an EnVision 2102 Multilabel Reader (PerkinElmer). Luminescence results were normalized to control. The quality and robustness of the assay was calculated using the Z′ factor and signal window (SW)

(Figure S2). Hit threshold was set above plate average signal of the compounds plus 3 times the standard deviation.

Drug selection

Computational analysis of potential false positives was performed in the compounds active in both the high-throughput small compound screen and in multiple assays, by comparison of the number of screens publicly available in PubChem (RRID:SCR_004284) and ChemBank (RRID:SCR_007592) databases. The activity of hits in the ChemBank screens was determined using an optimized B-score method that showed better performance than other hit identification methods. The activity of compounds in the PubChem bioassays was taken as provided by the database. After drug promiscuity assessment, drug targets were predicted using the software HitPick (Liu, Vogt, Haque & Campillos, 2013) (Figure S3). Final candidate drugs were selected based on the number 1) of hits of a Pubmed literature search composed by: "predicted target" + "COPD" or "predicted target" + "Wnt"; and 2) of predicted targets belonging to the gene ontology terms "epithelial cell proliferation" (GO:0050673) and "regulation of inflammatory response" (GO:0050727), relevant in COPD.

Reagents

CHIR99021 (Tocris), a GSK-3β inhibitor, amlexanox (Cayman Chemical), a IkappaB kinase epsilon (IKKε) and TANK binding kinase 1 (TBK1) inhibitor, nabumetone, a cyclooxygenase (COX) inhibitor, phenazopyridine hydrochloride, tolnaftate (Santa Cruz Biotechnology) and tiaprofenic acid (Sigma-Aldrich) were dissolved in DMSO to a stock concentration of 20 mM. PKF115-584 and iCRT14 (Tocris), antagonists of the TCF/β-catenin complex, were dissolved in DMSO to a stock concentration of 1 mM and 75 mM respectively. Lithium chloride (Sigma-Aldrich), a GSK-3β inhibitor, was dissolved in culture media to a stock solution of 2 M. Reagents were stored as stock solution at -20 °C.

Luciferase reporter assay

Leading Light Wnt Reporter cells were lysed with Glo Lysis Buffer (Promega) 24 hours after compound treatment. Luciferase activity was determined using a luminescence plate reader (Berthold Technologies) and the Bright-Glo Luciferase Assay System according to manufacturer's instructions. The measured values were analyzed with WinGlow Software, MikroWin 2000, version 4.41 (Berthold Technologies) and normalized to control. Quantifications were based on at least 3 independent experiments, each condition performed in triplicates.

Cell viability assay

Cell viability analysis was performed using CellTiter-Glo (Promega) according to the manufacturer's instructions, in NIH/3T3 cells. The assay was performed after 24 hours of compound treatment and measurements were done in triplicates. The measured values were analyzed with WinGlow Software, MikroWin 2000, version 4.41 (Berthold Technologies) and normalized to control. Quantifications are based on at least 3 independent experiments.

Animals

Eight to twelve weeks old pathogen-free wild type mice weighing 20 to 22 g were used in this study. C57BL/6N mice were purchased from Charles River Laboratories (Sulzfeld, Germany) and C57BL/6J mice from The Jackson Laboratory (Maine, USA, RRID:IMSR_JAX:000664). Animals were housed in rooms maintained at constant temperature and humidity, with a 12-hour light cycle and were allowed food and water *ad libitum*. Experiments were conducted under strict governmental and international guidelines, according to the regulatory guidelines of University of Colorado Institutional Animal Care and Use Committee. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny, Browne, Cuthill, Emerson, Altman & Group, 2010) and with the recommendations of the British Journal of Pharmacology.

Lung epithelial cell isolation

Lung epithelial cells were isolated as previously described (Messier, Mason & Kosmider, 2012; Mutze, Vierkotten, Milosevic, Eickelberg & Konigshoff, 2015; Ng-Blichfeldt et al., 2018) with

slight modifications. C57BL/6N female mice were anaesthetized with a mixture of 30m mg kg^{-1} body weight ketamine (Bela-pharm) and 100 mg kg^{-1} body weight xylazine (cp-pharma), sacrificed, through exsanguination by cutting the vena cava, and lungs were flushed with PBS. Mouse lungs were intratracheally inflated with dispase (BD Bioscience) followed by 300 µl instillation of 1% low gelling temperature agarose (A9414, Sigma Aldrich). Lungs were harvested, minced and filtered through 100 µm, 20 µm and 10 µm nylon meshes (Sefar). White blood cells were depleted with CD45 and epithelial cells were selected using CD326 (EpCAM) magnetic beads respectively (130–052-301, 130–105-958, Miltenyi Biotec), according to manufacturer's instructions. EpCAM$^+$ cells were resuspended in DMEM containing 2 mM L-alanyl-L-glutamine dipeptide (Gibco), 100 U ml^{-1} penicillin and streptomycin (Sigma Aldrich), 3.6 mg ml^{-1} glucose (Applichem) and 10 mM HEPES (Life Technologies) until further use.

Organoid culture

Organoids were cultured as previously described (Barkauskas et al., 2013; Hu et al., 2020; Ng-Blichfeldt et al., 2018) with some modifications. Briefly, MLg mouse lung fibroblasts were proliferation-inactivated by incubation in culture medium containing 10µg/ml mitomycin C (Merck) for 2 hours, followed by 3 washes in warm PBS (Life technologies), and let to recover in culture media for at least 1 hour. 20,000 EpCAM$^+$ cells suspended in 50 µl growth factor-reduced Matrigel (Corning) were diluted 1:1 with 20,000 MLg cells in 50 µl DMEM/F12 containing 10% (w/v) FBS and seeded into 24-well plate 0.4 µm pore transwell inserts (Corning). Cultures were maintained in DMEM/F12 containing 5% FBS, 100 U ml^{-1} penicillin/streptomycin, 2 mM L-alanyl-L-glutamine dipeptide (Gibco), 2.5 µg ml^{-1} amphotericin B (Gibco), 1x insulin-transferrin-selenium (Gibco), 0.025 µg ml^{-1} recombinant human EGF (Sigma), 0.1 µg ml^{-1} cholera toxin (Sigma-Aldrich), 30 µg ml^{-1} bovine pituitary extract (Sigma-Aldrich) and 0.01 µM of freshly added all-trans retinoic acid (Sigma-Aldrich) beneath the inserts. 10 µM Y-27632 (Tocris), a Rho-associated kinase (ROCK) inhibitor, was added to the media for the first 48 hours of culture. Treatments were added to the organoid media from day 0 and in every culture media exchange. Media was refreshed every 2-3 days.

Organoid quantification

Microscopy for organoid quantification at day 14 was performed using a microscope Axiovert 40 (Zeiss). Individual organoids from multi-layer Z-stacks, with a minimum size of 50 µm, were manually selected using the Fiji image processing package (Schindelin et al., 2012, RRID:SCR_002285). The total number of organoids was then normalized to treatment control.

Immunofluorescence

Immunofluorescence staining of organoids was performed as previously described (Ng-Blichfeldt et al., 2018). Organoids were kept in well inserts and fixed at day 14 with ice-cold acetone-methanol mixed 1:1 (AppliChem) for 15 minutes (min) at -20°C. Next, organoids were blocked with 5% (w/v) BSA (Sigma-Aldrich) dissolved in PBS, and further stored at 4°C. The following day, organoids were incubated with primary antibodies diluted in PBS with 0.1% (w/v) BSA and 0.1% (v/v) Triton X-100 solution (AppliChem) at 4°C. The next day, organoids were washed with PBS and incubated with secondary antibodies, diluted 1:200 at 4°C. Finally, on the third day cell nuclei were stained with 4'-6-diamidino-2-phenylindole, DAPI, (Roche) diluted 1:1000 for 10 min. Antibodies and dilutions used were: E-Cadherin 1:200 (610181, BD Bioscience, RRID:AB_397580), prosurfactant protein C 1:100 (AB3786, Millipore, RRID:AB_91588), acetylated alpha tubulin 1:2000 (ab24610, Abcam, RRID:AB_448182), donkey anti-mouse IgG conjugated with Alexa Fluor 647 1:200 (ab150107, Abcam, RRID:AB_2890037), goat anti-mouse IgG conjugated with Alexa Fluor 568 1:200 (A11031, Invitrogen, RRID:AB_144696) and goat anti-rabbit IgG conjugated with Alexa Fluor 488 1:200 (ab150077, Abcam, RRID:AB_2630356). Immunofluorescence was visualized using either a confocal microscope LSM710 or a microscope Axio Imager M2 (Zeiss). Images were processed using ImageJ (Schindelin, Rueden, Hiner & Eliceiri, 2015, RRID:SCR_003070).

Amlexanox preparation and *in vivo* administration

Amlexanox was administered to C57BL/6J mice by oral gavage as previously described (Reilly et al., 2013). Amlexanox was first dissolved in 150 mM NaOH, to a final concentration of 20

mg ml^{-1}. The solution was further diluted using a 1:1 mixture of water and 1.5 M Tris buffer pH 8.8, to achieve a final concentration of 10 mg ml^{-1}, which was further buffered to a pH of > 7.5 solution, to avoid amlexanox precipitation. Same solution without amlexanox was used as vehicle control. Mice were treated on a daily basis, from Day -1 (the day before elastase instillation) to Day 6, in a preventive regimen, either with 50 mg kg^{-1} amlexanox or vehicle. Mice were randomized and divided into the following groups: diseased controls (elastase challenged receiving vehicle) and diseased treated mice (elastase challenged receiving amlexanox treatment). Experiments were performed with 10 animals per group (5 male and 5 female). 1 mouse died before the end of the experiment, resulting in a final n of 9 for the amlexanox treatment group.

Elastase mouse model of emphysema

Emphysema was induced as described previously (Kneidinger et al., 2011). Elastase is an enzyme known to induce destruction of lung tissue. The elastase-induced injury model is widely used to study emphysema and well documented (Wright, Cosio & Churg, 2008). Shortly, porcine pancreatic elastase (Sigma-Aldrich) was dissolved in sterile PBS (Gibco) and applied orotracheally, 40 U kg^{-1} body weight in 80 µl PBS, in 3% isoflurane anaesthetized C57BL/6J mice. Animal health status and weights were closely monitored daily.

Lung function measurement

C57BL/6J mice were anaesthetized with ketamine-xylazine, tracheostomized, intubated and connected to a FlexiVent FX system (SCIREQ) (John-Schuster et al., 2014). Mice were ventilated with a tidal volume of 10 ml kg^{-1} at a frequency of 150 breaths min^{-1} to reach a mean lung volume similar to that of spontaneous breathing. Testing of lung mechanical properties including dynamic lung compliance and resistance was carried out by a software-generated script. Measurements were repeated four times per animal. The coefficient of determination (COD), a quality control parameter comparing the experimental signals and the lung function software models, was determined by the system. Only datasets with a coefficient higher than

0.95 were included in the analysis. Following lung function measurements, anaesthetized animals were sacrificed, and lungs were harvested.

Blinding

To decrease unintentional bias, personnel was blinded to experimental groups during sample processing and data analysis. During the blinding process, samples were randomly excluded so that sample sizes were the same between treatment groups during processing and analysis.

RNA extraction, cDNA synthesis and quantitative real-time PCR

Fresh lung tissue was snap frozen in liquid nitrogen and kept at −80 °C until further processing. Frozen tissue was pulverized using a TissueLyser II (Qiagen). Total RNA from lung tissue homogenate was isolated using QIAzol (Qiagen) and purified with the peqGOLD Total RNA Kit (Peqlab), according to the manufacturer's instructions. cDNA was synthesized using reverse transcription and M-MLV Reverse Transcriptase (Invitrogen). mRNA expression of target genes was compared with reference control hypoxanthine-guanine phosphoribosyltransferase (Hprt)-1, using SYBR Green (Roche) and a LC480 Light Cycler (Roche). Primers were used at a final concentration of 500 nM with the following sequences: *Hprt* forward 5'-CCTAAGATGAGCGCAAGTTGAA-3', reverse 5'-CCACAGGACTAGAACACCTGCTAA-3', *Axin2* forward 5'-AGCAGAGGGACAGGAACCA-3', reverse 5'-CTGAACCGATTCATGACCAC-3'*, Fzd4* forward 5'-TCCAGCCAGCTGCAGTTCTTCC-3', reverse 5'-CTGAAAGGCACATGCCACCGC-3', *Fgf7* forward 5'-AGGCTCAAGTTGCACGAGGC-3', reverse 5'-GCGGTTGCTCCTTGACTTTTGTT-3', *Hgf* forward 5'-TGCCTGTGCCTTGACTTAGCG-3', reverse 5'-CCGGGCTGAAAGAATCAAAGCA-3'*, Adamts4* forward 5'-AACCAAGCGCTTCGCTTCTCT-3' reverse 5'-AGCTGCCATAACCGTCAGCA-3' and *Eln* forward 5'-GGCGTCTTGCTGATCCTCT-3' reverse 5'-ATAATAGACTCCACCGGGAACT-3'.

Relative transcript expression of a gene was calculated as ΔCt (ΔCt = Ct reference gene – Ct target gene).

Mouse lung histology

Lungs were fixed at a constant pressure (20 cmH$_2$O) by intratracheal instillation of phosphate buffer solution (PBS)-buffered 6% paraformaldehyde (PFA). The trachea was sealed with a ligature, lungs and heart were removed en bloc, stored for 24h in 4% PFA and then kept in PBS at 4°C. Lobes were embedded into paraffin for histological analysis of hematoxylin-eosin (H&E)– stained slides (3 µm sections). Images were acquired at 10x and 20x magnifications using a microscope Axio Imager M2 (Zeiss). Images were processed using ImageJ (Schindelin, Rueden, Hiner & Eliceiri, 2015).

Statistical analysis

Data were analyzed using GraphPad Prism 9.1.0. (RRID:SCR_002798) and presented as mean ± SD. n is described in the figure legends and refers to number of independent experiments. Data from the luciferase reporter assay, cell viability assay and organoid number quantification was normalized to respective control treatment and analyzed using a one-sample Wilcoxon signed-rank test comparing to a hypothetical value of 1. For calculation of significances between different treatments a Kruskal-Wallis test, followed by a Dunn's multiple comparisons test was used. Mouse lung function, as well as mouse lung gene expression data were analyzed using a Mann-Whitney test. Differences at $p < 0.05$ were considered significant.

Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the Concise Guide to PHARMACOLOGY 2019/20 (Alexander et al., 2019).

Results

Wnt/β-catenin luciferase reporter cell-based screening identifies human approved drugs as Wnt activators

To identify novel compounds, which could activate Wnt/β-catenin signaling, we screened 1216 clinical approved drugs by the European Medicine Agency (EMA), Food and Drug Administration (FDA) and other agencies, using a Wnt luciferase reporter cell line (Figure 1a, b). The hit threshold for our assay was set above the mean signal of all compounds together, shifted by three times the standard deviation, specific for each assay plate. We identified 16 drugs that increased β-catenin-dependent luciferase activity (Figure 1c). 12 drugs decreased luciferase activity and were in the Wnt/β-catenin inhibitory range of the assay. Next, we selected five drugs out of the 16 hits based on the following algorithm: 1) promiscuity analysis in ChemBank and PubChem databases, regarding the ratio of the number of assays the hits were tested and active, to exclude potential false positives (Table S1); 2) predicted protein targets, using the bioinformatic tool HitPick (Figure S4); and 3) literature search, performed on the drug's predicted protein targets, associated either with the keywords "Wnt" or "COPD" or the GO terms "epithelial cell proliferation" or "regulation of inflammatory response", to study their potential involvement in the Wnt/β-catenin pathway and disease relevance (Figure 1a). The five selected candidate compounds were amlexanox, phenazopyridine hydrochloride, tolnaftate, nabumetone and tiaprofenic acid (Figure 1c, Table S2).

Inhibition of β-catenin reduces Wnt-dependent luciferase activity in amlexanox and phenazopyridine hydrochloride treated cells

Next, we aimed to validate that the candidate drugs amlexanox, phenazopyridine hydrochloride, tolnaftate, nabumetone and tiaprofenic acid, selected in our primary screen, regulate β-catenin signaling. To do so, we treated the Wnt/ β-catenin reporter cell line with the candidate drugs alone or together with PKF115-584, a well-known compound inhibiting the T cell factor (TCF)–β-catenin complex (Lepourcelet et al., 2004). In all compound treatments,

there was a significant increase in luciferase activity, confirming the results of our drug screen (Figure 2a). Wnt/β-catenin signaling induction was achieved in all compound concentrations, except for the lower dose of tiaprofenic acid. Inhibition of β-catenin led to a significant decrease in luciferase activity in both amlexanox and phenazopyridine hydrochloride treatments. For tolnaftate, nabumetone and tiaprofenic acid, there was also a decrease in luciferase activity, but not significant. At the same time, we observed that lithium chloride (LiCl), a classic inhibitor of GSK-3β and only patient-experienced drug known to activate Wnt/β-catenin signaling, induced luciferase activity in our reporter system, however had a lower luciferase activity induction compared to the candidate drugs. Second, the five selected candidate hits were analyzed in a concentration dependent manner with respect to their proliferative capacity, to rule out the possibility that the increase in luciferase activity was due to an increase in cell number (Figure 2a). We observed that there were no significant changes in the metabolic activity of the cells treated with the candidate drugs, measured by ATP levels, accounting both for proliferation and toxicity (Figure 2b). Based on these results, we focused our continued investigation on the compounds amlexanox and phenazopyridine hydrochloride.

Amlexanox and phenazopyridine hydrochloride induce primary adult lung epithelial cell driven organoid formation

We next investigated the potential implications of the candidate drugs for lung regeneration. Amlexanox and phenazopyridine hydrochloride, both of which showed previous β-catenin activation, were applied in a well-established 3D organoid assay using adult mouse epithelial cells (Figure 3a). We tested whether these compounds increase the number of distal lung organoids using a standard protocol including epithelial progenitor cells co-cultured with MLg lung fibroblasts cell line in Matrigel (Hu et al., 2020; Ng-Blichfeldt et al., 2018). Importantly, we and others have shown that organoid formation in this assay is dependent on Wnt/β-catenin signaling (Hu et al., 2020; Frank et al., 2016). We tested both compounds using two different concentrations, 0.5 and 1 μM, which were sufficient to induce Wnt/β-catenin signaling in the Wnt reporter luciferase assay (Figure 2a). Organoid formation quantified by number of

organoids was induced by LiCl (used as a positive control), as well as by amlexanox and lower doses of phenazopyridine hydrochloride (Figure 3b, c). In parallel, we observed that compound treatment for 14 days did not alter E-cadherin expression (Figure 3d). Organoids expressed lung epithelial cell markers for both acetylated alpha tubulin (ACT) and pro-surfactant C protein (SFTPC), markers for airway and alveolar epithelial cells respectively, as highlighted by the red and green arrows (Figure 3e). These results show that amlexanox and phenazopyridine hydrochloride can contribute to Wnt/β-catenin signaling driven lung progenitor cell function.

Inhibition of β-catenin reduces amlexanox and phenazopyridine hydrochloride organoid formation capacity

As described above, lung epithelial cell progenitor capability to form organoids *in vitro* requires Wnt/β-catenin signaling (Hu et al., 2020). We next determined whether induction of organoid formation by amlexanox and phenazopyridine hydrochloride was mediated by the Wnt pathway. To this end, we used a known potent Wnt/β-catenin signaling inhibitor iCRT14, which interferes with TCF binding to DNA in addition to influence TCF/β-catenin interaction (Gonsalves et al., 2011). iCRT14 treatment of organoids, significantly reduced organoid numbers when used alone, and importantly, also in combination with amlexanox or phenazopyridine hydrochloride (Figure 4a, b). These data further support the notion that the effect of both compounds on organoid formation is mediated by Wnt/β-catenin signaling.

Amlexanox treatment improves lung function and induces lung repair related genes while reducing disease markers in a mouse model of lung emphysema

Finally, we ask the question whether the regenerative effect observed with amlexanox in primary adult lung epithelial cell derived murine organoid cultures could also translated to *in vivo*. To address this, we used the well-accepted model of tissue destruction as seen in emphysema by subjecting mouse lungs to orotracheal administration of elastase (Kneidinger et al., 2011; Wright, Cosio & Churg, 2008) (Figure 5a). Mice were treated preventively with

50 mg kg^{-1} of amlexanox twice before being challenged with elastase and afterwards daily for 7 days. Notably, elastase challenged mice treated with amlexanox presented with improved lung function, as measured by a lower lung compliance when compared with mice treated only with vehicle (Figure 5b). Moreover, treatment with amlexanox also led to attenuated tissue destruction compared to the elastase vehicle group as observed by histology (Figure 5c). No changes were observed in healthy mice subjected to amlexanox, as shown in Figure S5 (lung function) and Figure S6 (lung structure). While we did not observe significant changes in Wnt target genes, such as *Axin2*, frizzled class receptor 4, *Fzd4, or fibroblast growth factor 7, Fgf7,* after 7 days treatment, we observed that amlexanox treatment led to a significant increase in the transcript expression of hepatocyte growth factor, *Hgf,* a protein which has been associated with lung repair (McQualter, Yuen, Williams & Bertoncello, 2010; Yanagita, Matsumoto, Sekiguchi, Ishibashi, Niho & Nakamura, 1993; Hegab et al., 2008) (Figure 5d)*.* Elastin, *Eln*, lung gene expression, a known marker of aberrant repair attempts in COPD (Houghton et al., 2006; Uhl et al., 2015) was significantly decreased with amlexanox treatment. Similar changes were observed with a lower dose of amlexanox (25 mg kg^{-1}, Figure S7).

Discussion and conclusions

The field of regenerative medicine is evolving rapidly with the growing understanding of molecular and cell-specific features during organ development, injury and regeneration, provided mainly by stem cell, single cell sequencing and cell tracing studies but also by the improvement of experimental models. On the other hand, drug development is still a long process, in particular for respiratory disease. Currently, the importance of rapid drug discovery for finding new treatments for emerging respiratory diseases, is being highlighted every day. Drug repurposing can shorten the drug development cycle from 10-17 years to 3-12 years and represents thus an advantageous approach (Dudley, Deshpande & Butte, 2011).

Our study provides an early proof-of-concept for the potential for rapid drug translation. Here, we identify amlexanox as a potential candidate for the treatment of lung emphysema, which is characterized by loss of lung tissue often found in COPD patients. We identified amlexanox as a potential drug for regenerative pharmacology using a drug screen based on Wnt/β-catenin signal activation.

Our unbiased drug screen approach identified 16 approved compounds that were able to significantly induce Wnt-dependent luciferase activity. Our results overlap with other studies performing similar Wnt/β-catenin-based independent screening in cells (Figure S8), which reinforces the reproducibility of our findings (Biechele et al., 2010; Zhan et al., 2019; Zhao, Cheng, Theriault, Sheridan, Tsai & Haggarty, 2012). Unique compounds identified in our screen are likely due to differences in the drug screen set up with distinct results based on the cell line used, or chemical library applied. Furthermore, only compounds which showed no promiscuity in publicly available bioassays, were considered in our study. Thus, we focused on drugs with specific effect on Wnt/β-catenin signaling, rather than an overall interference with gene transcription or protein translation. We selected five candidate drugs based on a platform for target prediction called HitPick (Liu, Vogt, Haque & Campillos, 2013). Using HitPick, targets are predicted by molecular comparison of the hits to other compounds for which targets are known. After a literature search, hits in which predicted targets were found

to be associated with either "Wnt" or "COPD" or belonging to the GO terms "epithelial cell proliferation" or "regulation of inflammatory response" were selected. Our approach is in line with recent strategies in place for computational drug repurposing (Dudley, Deshpande & Butte, 2011). We have incorporated both drug-based strategies, through chemical similarities with other compounds for target prediction, as well as disease-based strategies, through the association of the hits' predicted targets to current knowledge of disease and pathology, to select final drug candidates with strong potential for COPD/emphysema treatment.

We focused our further analysis on amlexanox, phenazopyridine hydrochloride, tolnaftate, nabumetone and tiaprofenic acid. All five drugs induced Wnt/β-catenin reporter luciferase activity in a confirmatory screening, using the same cell line we used in the initial screen. To exclude the possibility that luciferase increases were due to cell proliferation, we measured ATP changes after drug treatment and we did not observe significant increase in number of cells, as demonstrated by cell metabolic activity (Rulifson et al., 2007).

Upon Wnt/β-catenin signaling inhibition, two of the five compounds showed a significant decrease of their capacity to induce Wnt/β-catenin capacity in the monocultures. On the one hand this indicates Wnt/β-catenin specificity, but on the other hand it could represent a challenge in the disease context, where the tissue environment contains factors, which dampen Wnt/β-catenin signaling (Baarsma et al., 2017). This may indicate that a multi-targeted approach is necessary using a combination of pharmacological approaches to initiate functional repair.

Our initial screen was based on results observed in embryonic fibroblasts, so we applied a lung epithelial cell based organoid assay, to validate our findings in a primary cell setup and further to predict pharmacological effects which could not be detected in a 2D. Importantly, we and others have demonstrated that organoid formation in this system requires Wnt/β-catenin signaling (Hu et al., 2020; Frank et al., 2016). Both amlexanox and phenazopyridine hydrochloride exhibited a significant increase in lung organoid formation, and led to differentiation of adult epithelial cells, indicating a potential to induce lung regeneration. E-

cadherin protein expression is essential in maintaining epithelial tissue integrity and known to be reduced in many epithelial cell malignancies, such as cancer (Yu, Yang, Li & Zhang, 2019). In our hands, Wnt/β-catenin signaling activation using amlexanox and phenazopyridine hydrochloride did not seem to have an effect on e-cadherin expression in adult lung epithelial cells. Since amlexanox performed better in the organoid assay than phenazopyridine hydrochloride, we selected amlexanox for further investigation *in vivo*.

Our *in vivo* results demonstrate that amlexanox treatment attenuates emphysema development potentially by initiating a pro-regenerative environment in the lung. Importantly, mice upon amlexanox treatment exhibited improved lung function and structure. In line with this, we observed transcriptional changes in several genes previously implicated in emphysema and COPD (Barnes et al., 2014; Ezzie et al., 2012; Houghton et al., 2006). Among these, HGF is well-described as a primarily mesenchyme-produced factor that has been implicated in adult lung repair (McQualter, Yuen, Williams & Bertoncello, 2010; Yanagita, Matsumoto, Sekiguchi, Ishibashi, Niho & Nakamura, 1993; Hegab et al., 2008). The increase in HGF observed *in vivo*, points to potential additional effects of amlexanox - either directly on mesenchymal (or other) cells, or indirectly due to changes in (Wnt/β-catenin-driven) lung epithelial signalling induced by amlexanox. Along these lines, it is important to note that our organoid system includes a fibroblast cell line as support cells, and we have previously found that HGF expression from fibroblasts contribute to organoid formation (Ng-Blichfeldt et al., 2019). A stromal-free lung epithelial progenitor cell culture (McQualter, Yuen, Williams & Bertoncello, 2010) could be helpful to further dissect the impact of amlexanox on epithelial versus stromal cells to induce organoid formation and lung repair.

We did not observe changes in Wnt target genes in our study when analysing lung tissue 7 days after amlexanox treatment. This might be due to the temporal expression of Wnt/β-catenin targets gene, which are described to be direct feedback genes (Katoh, 2008; Pedone & Marucci, 2019). However, future studies are needed that expand on *in vivo* monitoring of Wnt/β-catenin activity upon amlexanox treatment.

Amlexanox is clinically used for the treatment of aphthous ulcers, allergic rhinitis and asthma. The drug is described to be anti-inflammatory and anti-allergic with immunomodulatory properties. The mechanism of action has been described to be through reduction of the release of histamine and leukotrienes (Inagaki et al., 1992). Different studies indicate that amlexanox administration is associated with weight loss and inflammation reduction (Ozasa et al., 2019; Reilly et al., 2013). Currently, amlexanox is under clinical trial for the treatment of type 2 diabetes and obesity (NCT01842282). Amlexanox was shown to have a bronchodilator effect in aspirin-induced asthma patients (Imokawa et al., 1993). Therapeutic targeting leukotrienes in COPD is sometimes an option, as it has anti-inflammatory as well as bronchodilator effects on the airway in a few subsets of patients (Lee, Kim & Kim, 2015). Only recently, a study demonstrated that amlexanox acts as a Wnt/β-catenin signaling activation (Bordonaro & Lazarova, 2019). Wnt/β-catenin signaling induction by amlexanox has been described to be mediated by inhibition of IKKε/TBK1 (Reilly et al., 2013). IKKε is known to interact with β-catenin (Chen et al., 2017). Additionally, IKKε and TBK1 can activate interferon regulatory factor 3 (IRF3) signaling (Fitzgerald et al., 2003). Inhibition of both these processes has been shown to lead to β-catenin signaling activation (Chen et al., 2017; Tian et al., 2020). It is important to note that these mechanisms need to be further confirmed in the lung.

In the present study we focused mainly on the phenotypic effect of amlexanox. Our data add to the recent observations that epithelial (progenitor) cells exhibit active Wnt/β-catenin signaling capacity. A recent study characterized stem cell clone libraries of COPD patient's lungs in advanced stages and identified normal lung stem cells present and three more predominant pathogenic stem cell variants (Rao et al., 2020). These stem cell variants were found to contribute to COPD and targeting them represents an opportunity to treat the disease. This study indicates however that COPD patients retain normal lung stem cell niches that could potentially regenerate the lung. Discovery of Wnt/β-catenin signaling modulators that selectively affect one or more of these cell populations could potentially induce regeneration in an adult and diseased lung.

Our study adds to a growing body of evidence that Wnt/β-catenin pathway modulation can be harnessed for the induction of lung regeneration in lung emphysema. However, certain limitations of our study need to be addressed in the future to further our understanding of amlexanox as a potential therapeutic: further *in vivo* analysis using therapeutic *versus* preventive approaches in COPD/emphysema models, including the cigarette smoke exposure model. Moreover, *ex vivo* studies regarding regenerative potential COPD patient's lungs are needed to understand the regenerative potential of amlexanox in the lung. This could be done by using organoids derived from COPD/emphysema lungs and/or tissue-based models derived from COPD. For example, we have previously shown that Wnt/β-catenin signal activation and lung repair can be achieved by the GSK-3β inhibitor lithium chloride in COPD patient-derived precision-cut lung slices (Uhl et al., 2015).

In summary, amlexanox was identified as a potential new candidate for the treatment of lung emphysema based on a combination of different phenotypic and computational readouts. Many other undiscovered applications of already approved drugs exist, and drug discovery approaches as described in this study, are important and necessary step towards therapeutic advances for patients with emphysema and COPD.

References

Agusti A, & Hogg JC (2019). Update on the Pathogenesis of Chronic Obstructive Pulmonary Disease. N Engl J Med 381**:** 1248-1256.

Alexander SPH, Roberts RE, Broughton BRS, Sobey CG, George CH, Stanford SC, et al. (2018). Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology. British journal of pharmacology 175: 407-411.

Baarsma HA, & Konigshoff M (2017). 'WNT-er is coming': WNT signalling in chronic lung diseases. Thorax 72**:** 746-759.

Baarsma HA, Skronska-Wasek W, Mutze K, Ciolek F, Wagner DE, John-Schuster G*, et al.* (2017). Noncanonical WNT-5A signaling impairs endogenous lung repair in COPD. J Exp Med 214**:** 143-163.

Barkauskas CE, Cronce MJ, Rackley CR, Bowie EJ, Keene DR, Stripp BR*, et al.* (2013). Type 2 alveolar cells are stem cells in adult lung. The Journal of clinical investigation 123**:** 3025-3036.

Barnes PJ (2014). Hepatocyte growth factor deficiency in COPD: a mechanism of emphysema and small airway fibrosis? Chest 146**:** 1135-1136.

Barnes PJ, Bonini S, Seeger W, Belvisi MG, Ward B, & Holmes A (2015). Barriers to new drug development in respiratory disease. Eur Respir J 45**:** 1197-1207.

Biechele TL, Camp ND, Fass DM, Kulikauskas RM, Robin NC, White BD*, et al.* (2010). Chemical-genetic screen identifies riluzole as an enhancer of Wnt/beta-catenin signaling in melanoma. Chem Biol 17**:** 1177-1182.

Bordonaro M, & Lazarova D (2019). Amlexanox and UPF1 Modulate Wnt Signaling and Apoptosis in HCT-116 Colorectal Cancer Cells. J Cancer 10**:** 287-292.

Celli BR, & Wedzicha JA (2019). Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. N Engl J Med 381**:** 1257-1266.

Chen J, Zhao J, Chen X, Ding C, Lee K, Jia Z, et al. (2017). Hyper activation of beta-catenin signalling induced by IKKepsilon inhibition thwarts colorectal cancer cell proliferation. Cell Prolif 50.

Conlon TM, John-Schuster G, Heide D, Pfister D, Lehmann M, Hu Y, et al. (2020). Inhibition of LTbetaR signalling activates WNT-induced regeneration in lung. Nature 588: 151-156.

De Meyer I, Martinet W, Van Hove CE, Schrijvers DM, Hoymans VY, Van Vaeck L*, et al.* (2011). Inhibition of inositol monophosphatase by lithium chloride induces selective macrophage apoptosis in atherosclerotic plaques. Br J Pharmacol 162**:** 1410-1423.

Dudley JT, Deshpande T, & Butte AJ (2011). Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform 12**:** 303-311.

Ezzie ME, Crawford M, Cho JH, Orellana R, Zhang S, Gelinas R*, et al.* (2012). Gene expression networks in COPD: microRNA and mRNA regulation. Thorax 67**:** 122-131.

Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, et al. (2003). IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 4: 491-496.

Frank DB, Peng T, Zepp JA, Snitow M, Vincent TL, Penkala IJ, et al. (2016). Emergence of a Wave of Wnt Signaling that Regulates Lung Alveologenesis by Controlling Epithelial Self-Renewal and Differentiation. Cell Rep 17: 2312-2325.

Gonsalves FC, Klein K, Carson BB, Katz S, Ekas LA, Evans S*, et al.* (2011). An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc Natl Acad Sci U S A 108**:** 5954-5963.

Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S, et al. (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res 46: D1091-D1106.

Hegab AE, Kubo H, Yamaya M, Asada M, He M, Fujino N*, et al.* (2008). Intranasal HGF administration ameliorates the physiologic and morphologic changes in lung emphysema. Mol Ther 16**:** 1417-1426.

Hind M, & Maden M (2011). Is a regenerative approach viable for the treatment of COPD? Br J Pharmacol 163**:** 106-115.

Houghton AM, Quintero PA, Perkins DL, Kobayashi DK, Kelley DG, Marconcini LA*, et al.* (2006). Elastin fragments drive disease progression in a murine model of emphysema. The Journal of clinical investigation 116**:** 753-759.

Hu Y, Ng-Blichfeldt JP, Ota C, Ciminieri C, Ren W, Hiemstra PS, *et al.* (2020). Wnt/beta-catenin signaling is critical for regenerative potential of distal lung epithelial progenitor cells in homeostasis and emphysema. Stem Cells.

Imokawa S, Satou A, Taniguchi M, Toyoshima M, Nakazawa K, Hayakawa H, *et al.* (1993). [Amlexanox has an acute bronchodilator effect in patients with aspirin-induced asthma (AIA)]. Nihon Kyobu Shikkan Gakkai Zasshi 31**:** 976-982.

Inagaki M, Michimata H, Minato K, Sunaga Y, Kobayashi S, Tani G, *et al.* (1992). [Inhibitory effect of amlexanox on asthmatic attacks in an aspirin sensitive asthmatic]. Nihon Kyobu Shikkan Gakkai Zasshi 30**:** 1180-1185.

Jiang Z, Lao T, Qiu W, Polverino F, Gupta K, Guo F, *et al.* (2016). A Chronic Obstructive Pulmonary Disease Susceptibility Gene, FAM13A, Regulates Protein Stability of beta-Catenin. Am J Respir Crit Care Med 194**:** 185-197.

John-Schuster G, Hager K, Conlon TM, Irmler M, Beckers J, Eickelberg O, *et al.* (2014). Cigarette smoke-induced iBALT mediates macrophage activation in a B cell-dependent manner in COPD. Am J Physiol Lung Cell Mol Physiol 307**:** L692-706.

Katoh M (2008). WNT signaling in stem cell biology and regenerative medicine. Curr Drug Targets 9: 565-570.

Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, & Group NCRRGW (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160**:** 1577-1579.

Kneidinger N, Yildirim AO, Callegari J, Takenaka S, Stein MM, Dumitrascu R, *et al.* (2011). Activation of the WNT/beta-catenin pathway attenuates experimental emphysema. Am J Respir Crit Care Med 183**:** 723-733.

Lee JH, Kim HJ, & Kim YH (2015). The Effectiveness of Anti-leukotriene Agents in Patients with COPD: A Systemic Review and Meta-analysis. Lung 193**:** 477-486.

Lehmann M, Hu Q, Hu Y, Hafner K, Costa R, van den Berg A, *et al.* (2020). Chronic WNT/beta-catenin signaling induces cellular senescence in lung epithelial cells. Cell Signal 70**:** 109588.

Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, *et al.* (2004). Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 5**:** 91-102.

Li X, Cao X, Guo M, Xie M, & Liu X (2020). Trends and risk factors of mortality and disability adjusted life years for chronic respiratory diseases from 1990 to 2017: systematic analysis for the Global Burden of Disease Study 2017. BMJ 368**:** m234.

Liu Q, Liu K, Cui G, Huang X, Yao S, Guo W, *et al.* (2019). Lung regeneration by multipotent stem cells residing at the bronchioalveolar-duct junction. Nat Genet 51**:** 728-738.

Liu X, Vogt I, Haque T, & Campillos M (2013). HitPick: a web server for hit identification and target prediction of chemical screenings. Bioinformatics 29**:** 1910-1912.

McQualter JL, Yuen K, Williams B, & Bertoncello I (2010). Evidence of an epithelial stem/progenitor cell hierarchy in the adult mouse lung. Proc Natl Acad Sci U S A 107: 1414-1419.

Messier EM, Mason RJ, & Kosmider B (2012). Efficient and rapid isolation and purification of mouse alveolar type II epithelial cells. Exp Lung Res 38**:** 363-373.

Mutze K, Vierkotten S, Milosevic J, Eickelberg O, & Konigshoff M (2015). Enolase 1 (ENO1) and protein disulfide-isomerase associated 3 (PDIA3) regulate Wnt/beta-catenin-driven trans-differentiation of murine alveolar epithelial cells. Dis Model Mech 8**:** 877-890.

Nabhan AN, Brownfield DG, Harbury PB, Krasnow MA, & Desai TJ (2018). Single-cell Wnt signaling niches maintain stemness of alveolar type 2 cells. Science 359**:** 1118-1123.

Ng-Blichfeldt JP, de Jong T, Kortekaas RK, Wu X, Lindner M, Guryev V, et al. (2019). TGF-beta activation impairs fibroblast ability to support adult lung epithelial progenitor cell organoid formation. Am J Physiol Lung Cell Mol Physiol 317: L14-L28.

Ng-Blichfeldt JP, Gosens R, Dean C, Griffiths M, & Hind M (2019). Regenerative pharmacology for COPD: breathing new life into old lungs. Thorax 74**:** 890-897.

Ng-Blichfeldt JP, Schrik A, Kortekaas RK, Noordhoek JA, Heijink IH, Hiemstra PS*, et al.* (2018). Retinoic acid signaling balances adult distal lung epithelial progenitor cell growth and differentiation. EBioMedicine 36**:** 461-474.

Ozasa K, Temizoz B, Kusakabe T, Kobari S, Momota M, Coban C*, et al.* (2019). Cyclic GMP-AMP Triggers Asthma in an IL-33-Dependent Manner That Is Blocked by Amlexanox, a TBK1 Inhibitor. Front Immunol 10**:** 2212.

Pedone E, & Marucci L (2019). Role of beta-Catenin Activation Levels and Fluctuations in Controlling Cell Fate. Genes (Basel) 10.

Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A*, et al.* (2019). Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18**:** 41-58.

Quaderi SA, & Hurst JR (2018). The unmet global burden of COPD. Glob Health Epidemiol Genom 3**:** e4.

Rao W, Wang S, Duleba M, Niroula S, Goller K, Xie J*, et al.* (2020). Regenerative Metaplastic Clones in COPD Lung Drive Inflammation and Fibrosis. Cell 181**:** 848-864 e818.

Reilly SM, Chiang SH, Decker SJ, Chang L, Uhm M, Larsen MJ*, et al.* (2013). An inhibitor of the protein kinases TBK1 and IKK-varepsilon improves obesity-related metabolic dysfunctions in mice. Nat Med 19**:** 313-321.

Rulifson IC, Karnik SK, Heiser PW, ten Berge D, Chen H, Gu X*, et al.* (2007). Wnt signaling regulates pancreatic beta cell proliferation. Proc Natl Acad Sci U S A 104**:** 6247-6252.

Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T*, et al.* (2012). Fiji: an open-source platform for biological-image analysis. Nat Methods 9**:** 676-682.

Schindelin J, Rueden CT, Hiner MC, & Eliceiri KW (2015). The ImageJ ecosystem: An open platform for biomedical image analysis. Mol Reprod Dev 82**:** 518-529.

Siddiqui FM, & Diamond JM (2018). Lung transplantation for chronic obstructive pulmonary disease: past, present, and future directions. Curr Opin Pulm Med 24**:** 199-204.

Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR*, et al.* (2019). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J 53.

Skronska-Wasek W, Mutze K, Baarsma HA, Bracke KR, Alsafadi HN, Lehmann M*, et al.* (2017). Reduced Frizzled Receptor 4 Expression Prevents WNT/beta-Catenin-driven Alveolar Lung Repair in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 196**:** 172-185.

Tian M, Wang X, Sun J, Lin W, Chen L, Liu S, et al. (2020). IRF3 prevents colorectal tumorigenesis via inhibiting the nuclear translocation of beta-catenin. Nat Commun 11: 5762.

Uhl FE, Vierkotten S, Wagner DE, Burgstaller G, Costa R, Koch I, *et al.* (2015). Preclinical validation and imaging of Wnt-induced repair in human 3D lung tissue cultures. Eur Respir J 46**:** 1150-1166.

Wang R, Ahmed J, Wang G, Hassan I, Strulovici-Barel Y, Hackett NR, *et al.* (2011). Down-regulation of the canonical Wnt beta-catenin pathway in the airway epithelium of healthy smokers and smokers with COPD. PLoS One 6**:** e14793.

Wright JL, Cosio M, & Churg A (2008). Animal models of chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol 295**:** L1-15.

Yanagita K, Matsumoto K, Sekiguchi K, Ishibashi H, Niho Y, & Nakamura T (1993). Hepatocyte growth factor may act as a pulmotrophic factor on lung regeneration after acute lung injury. J Biol Chem 268: 21212-21217

Yu W, Yang L, Li T, & Zhang Y (2019). Cadherin Signaling in Cancer: Its Functions and Role as a Therapeutic Target. Front Oncol 9**:** 989.

Zacharias WJ, Frank DB, Zepp JA, Morley MP, Alkhaleel FA, Kong J, *et al.* (2018). Regeneration of the lung alveolus by an evolutionarily conserved epithelial progenitor. Nature 555**:** 251-255.

Zhan T, Ambrosi G, Wandmacher AM, Rauscher B, Betge J, Rindtorff N, *et al.* (2019). MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer. Nat Commun 10**:** 2197.

Zhao WN, Cheng C, Theriault KM, Sheridan SD, Tsai LH, & Haggarty SJ (2012). A high-throughput screen for Wnt/beta-catenin signaling pathway modulators in human iPSC-derived neural progenitors. J Biomol Screen 17**:** 1252-1263.

Figure 1. High-throughput drug screen and candidate compound selection. a) Diagram with outline of candidate compound identification and selection process. Hits were identified following a cell based Wnt reporter FDA, EMA and other agencies-approved drug screen and candidates were selected based on their predicted protein targets (HitPick), associated with either "Wnt", "COPD", "epithelial cell proliferation" or "regulation of inflammation". b) Schematic overview of the drug screening experimental procedure. Leading light Wnt Reporter Cell Line, expressing firefly luciferase reporter gene under the control of Wnt-responsive promoters (TCF/LEF) was seeded in a 384 well-plate, serum starved (0.1% FBS) for 24 hours and treated for another 24 hours with 10 μM of each compound belonging to Prestwick chemical library, including approved drugs by EMA, FDA and other agencies. Luciferase assay was performed, luminescence values were analyzed and luciferase activity was calculated relative to negative control (dimethyl sulfoxide, DMSO). 10 μM CHIR99021 was used as positive control. c) Results of the cell based Wnt reporter drug screen. n=1. Luciferase activity represents the calculated Z-score for the luminescence signal of each compound treatment relative to control. Hits Z-score was set as greater than the average signal of all compounds plus three times the standard deviation. Compound screen identified 16 Wnt/β-catenin/TCF/LEF activators. White dots highlight the five selected candidate compounds: amlexanox, phenazopyridine hydrochloride, tolnaftate, nabumetone and tiaprofenic acid.

Figure 2. Confirmation of selected candidate compounds: Wnt modulation and metabolic activity. a) Luciferase assay in Leading Light Wnt Reporter Cell Line treated with 0.5, 1, 5, or 10 µM of candidate compounds for 24 hours with or without 1 µM PKF115-584, calphostin C, an antagonist of TCF/β-catenin complex. GSK-3β inhibitors, 1 µM CHIR99021 and 10mM LiCl were used as positive controls. Luciferase activity was calculated relative to negative control (DMSO). n=3-10. b) Metabolic activity of NIH/3T3 cells treated with 0.5, 1, 5, or 10 µM of candidate compounds for 24 hours was evaluated by ATP levels, measured with cell titer glo luminescent cell viability assay. 1 µM CHIR99021 was used as a positive control. Metabolic activity was calculated relative to negative control (DMSO). n=4. One sample Wilcoxon signed-rank test to an hypothetical value of 1, *p<0.05, **p<0.01 and Kruskal-Wallis test with Dunn's post test, #p<0.05. Data is presented as mean ± SD of independent experiments. Control (DMSO), lithium chloride (LiCl), amlexanox (AML), phenazopyridine hydrochloride (PHE), tolnaftate (TOL), nabumetone (NAB) and tiaprofenic acid (TIA).

Figure 3. Compound alveolar regeneration potential in primary mouse alveolar type II cell derived 3D lung organoids. a) Schematic of mouse organoid experimental setup. Primary mouse ATII cells were isolated from 10-12 weeks old wild type C57BL/6 mice lungs after enzymatic dissociation with dispase and MACS sorting of CD45 negative and EpCAM positive cells. Cells were seeded in matrigel together with non-proliferative CCL206 lung fibroblasts in well inserts. Media with treatments was changed every second to third day. Adapted from Lehmann et al. (Lehmann et al., 2020). b) Representative phase contrast images of whole insert organoids (top) and inset images (bottom). Treatments with DMSO, 10 mM LiCl, 0.5 and 1 µM amlexanox and 0.5 and 1 µM Phenazopyridine hydrochloride started at day 0 and continued every 2nd to 3rd day for 14 days. Scale bar = 500 µm, n=3-14. c) Normalized total number of organoids per insert to control (DMSO). n=3-14 from individual cell isolations. One sample Wilcoxon signed-rank test to an hypothetical value of 1, *p<0.05. d) Maximum intensity projection images of whole mount immunofluorescence stainings of day 14 organoids. E-cadherin (red) and DAPI (blue). Scale bar = 100 µm. n=3. e) Images from whole mount immunofluorescent stained day 14 organoids. Pro-surfactant protein C (SFTPC, green), acetylated alpha tubulin (ACT, red) and DAPI (DNA, blue). Scale bar = 100 µm, n=3. Lithium chloride (LiCl), amlexanox (AML) and phenazopyridine hydrochloride (PHE).

Figure 4. Wnt modulation and organoid formation. a) Representative phase contrast images of whole insert day 14 organoids after 0.5 µM candidate compound treatment amlexanox and phenazopyridine hydrochloride with or without 10 µM iCRT14, a potent Wnt inhibitor which blocks β–catenin/TCF4 binding. Scale bar = 500 µm. b) Normalized total number of organoids per insert to control (DMSO), n=2-14. Data is presented as box plots with median of independent experiments. One sample Wilcoxon signed-rank test to an hypothetical value of 1, *p<0.05. Amlexanox (AML) and phenazopyridine hydrochloride (PHE).

Figure 5. Amlexanox *in vivo* functional assessment in a mouse model of emphysema.

a) Schematic overview of wild type C57BL/6 mice treated with amlexanox. Mice were treated preventively either with 50 mg kg[-1] of amlexanox or vehicle a day before being challenged with 40 U kg[-1] body weight of porcine pancreatic elastase and every day for 7 days via oral gavage. Lung function and gene expression was analyzed. b) Dynamic compliance from lung function analysis. n=10. c) Representative histological images of mice lung sections stained with hematoxylin and eosin. n=4-5. Scale bar =100 μm. d) Lung gene expression analysis of Wnt, tissue repair and COPD related genes *Axin2*, *Fzd4*, *Fgf7*, *Hgf, Adamts4* and *Eln*. n=8-9. Data is presented as mean ± SD. Mann-Whitney test, *p<0.05, **p<0.01.